Piramal Enterprises Limited (PEL.NS)
INR 978.0
(1.04%)
INR 978.0
(1.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 560.47 Billion INR | -98.79% |
| 2022 | 46457.61 Billion INR | 7270.01% |
| 2021 | 630.36 Billion INR | 50.16% |
| 2020 | 419.79 Billion INR | -5.32% |
| 2019 | 443.36 Billion INR | -24.03% |
| 2018 | 583.64 Billion INR | 26.26% |
| 2017 | 462.26 Billion INR | 38.64% |
| 2016 | 333.43 Billion INR | 81.41% |
| 2015 | 183.79 Billion INR | 100.42% |
| 2014 | 91.7 Billion INR | -24.65% |
| 2013 | 121.71 Billion INR | 27.92% |
| 2012 | 95.14 Billion INR | 176.22% |
| 2011 | 34.44 Billion INR | 71.41% |
| 2010 | 20.09 Billion INR | -7.3% |
| 2009 | 21.67 Billion INR | -5.26% |
| 2008 | 22.88 Billion INR | 61.87% |
| 2007 | 14.13 Billion INR | 14.75% |
| 2006 | 12.31 Billion INR | 45.01% |
| 2005 | 8.49 Billion INR | 11.95% |
| 2004 | 7.58 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 598.26 Billion INR | 325.27% |
| 2024 Q1 | -265.57 Billion INR | -147.38% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 560.47 Billion INR | 0.0% |
| 2023 FY | 560.47 Billion INR | -98.79% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 529.34 Billion INR | 0.0% |
| 2022 Q2 | 529.17 Billion INR | 0.0% |
| 2022 Q4 | 46457.61 Billion INR | 5859.92% |
| 2022 FY | 46457.61 Billion INR | 7270.01% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | 779.5 Billion INR | 47.31% |
| 2021 Q4 | 630.36 Billion INR | 0.0% |
| 2021 Q2 | 694.84 Billion INR | 0.0% |
| 2021 FY | 630.36 Billion INR | 50.16% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 419.79 Billion INR | -5.32% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 452 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 419.79 Billion INR | 0.0% |
| 2019 FY | 443.36 Billion INR | -24.03% |
| 2019 Q2 | 551.93 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 443.36 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 547.39 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 583.64 Billion INR | 0.0% |
| 2018 FY | 583.64 Billion INR | 26.26% |
| 2017 Q2 | 416.79 Billion INR | 0.0% |
| 2017 Q3 | 394.55 Billion INR | -5.34% |
| 2017 Q4 | 462.26 Billion INR | 17.16% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 462.26 Billion INR | 38.64% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 333.43 Billion INR | 81.41% |
| 2016 Q4 | 333.43 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 315.98 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 183.79 Billion INR | 100.42% |
| 2015 Q4 | 183.79 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 62.92 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 91.7 Billion INR | 0.0% |
| 2014 FY | 91.7 Billion INR | -24.65% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 74.61 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 109.77 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 121.71 Billion INR | 27.92% |
| 2013 Q4 | 121.71 Billion INR | 0.0% |
| 2012 FY | 95.14 Billion INR | 176.22% |
| 2012 Q4 | 95.14 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 6.91 Billion INR | 0.0% |
| 2011 Q4 | 34.44 Billion INR | 0.0% |
| 2011 FY | 34.44 Billion INR | 71.41% |
| 2010 FY | 20.09 Billion INR | -7.3% |
| 2009 FY | 21.67 Billion INR | -5.26% |
| 2008 FY | 22.88 Billion INR | 61.87% |
| 2007 FY | 14.13 Billion INR | 14.75% |
| 2006 FY | 12.31 Billion INR | 45.01% |
| 2005 FY | 8.49 Billion INR | 11.95% |
| 2004 FY | 7.58 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 783.82 Million INR | -71405.784% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -193972.521% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -15888.119% |
| FDC Limited | 3.7 Billion INR | -15010.49% |
| Gufic Biosciences Limited | 5.59 Billion INR | -9908.902% |
| Hikal Limited | 12.99 Billion INR | -4213.073% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -24380.849% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -8755.875% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -86946.793% |
| Medico Remedies Limited | 438.24 Million INR | -127792.11% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -4896.214% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -350657.865% |
| RPG Life Sciences Limited | 1.38 Billion INR | -40508.571% |
| Sequent Scientific Limited | 8.27 Billion INR | -6673.78% |
| Shilpa Medicare Limited | 12.93 Billion INR | -4233.891% |
| Sigachi Industries Limited | 2.53 Billion INR | -22042.269% |
| Themis Medicare Limited | 1.88 Billion INR | -29594.105% |
| Unichem Laboratories Limited | 8.06 Billion INR | -6845.866% |
| Venus Remedies Limited | 1.39 Billion INR | -40141.205% |
| Wanbury Limited | 3.15 Billion INR | -17661.891% |
| ZIM Laboratories Limited | 2.08 Billion INR | -26836.262% |
| Lupin Limited | 96.23 Billion INR | -482.393% |
| Innova Captab Limited | 4.89 Billion INR | -11338.661% |
| Ind-Swift Limited | 13.45 Billion INR | -4066.215% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -11414.333% |
| Aurobindo Pharma Limited | 152.2 Billion INR | -268.235% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -3877.345% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -15209.009% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -28259.884% |
| Morepen Laboratories Limited | 4.45 Billion INR | -12467.399% |
| Laurus Labs Limited | 42.71 Billion INR | -1212.15% |
| Aarti Drugs Limited | 11.5 Billion INR | -4772.04% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -10718.188% |
| Alembic Limited | 1.43 Billion INR | -39036.897% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -3344.06% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -760.809% |
| Vaishali Pharma Limited | 371.16 Million INR | -150906.296% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -6693.115% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -188766.256% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -814.71% |
| Eris Lifesciences Limited | 38.26 Billion INR | -1364.614% |
| Windlas Biotech Limited | 1.76 Billion INR | -31696.647% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | -205.323% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -52059.705% |
| Orchid Pharma Limited | 3.84 Billion INR | -14480.336% |
| Albert David Limited | 1.15 Billion INR | -48632.898% |
| Hester Biosciences Limited | 3.59 Billion INR | -15491.743% |
| Sakar Healthcare Limited | 1.26 Billion INR | -44267.005% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -27452.429% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -21783.473% |
| Divi's Laboratories Limited | 18.99 Billion INR | -2851.445% |
| Mankind Pharma Limited | 23.87 Billion INR | -2247.591% |
| Neuland Laboratories Limited | 5.49 Billion INR | -10093.201% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -5134.213% |
| Zydus Lifesciences Limited | 71.79 Billion INR | -680.699% |
| Wockhardt Limited | 39.87 Billion INR | -1305.767% |
| Bal Pharma Limited | 2.51 Billion INR | -22218.515% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | -423.969% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -26477.482% |
| Alkem Laboratories Limited | 48.6 Billion INR | -1053.131% |
| Valiant Laboratories Limited | 1.05 Billion INR | -52862.313% |
| Ajanta Pharma Limited | 10.71 Billion INR | -5133.089% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -85826.344% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -32444.627% |
| Granules India Limited | 22.95 Billion INR | -2341.71% |
| Medicamen Biotech Limited | 940.36 Million INR | -59502.208% |
| Ipca Laboratories Limited | 33.74 Billion INR | -1561.034% |
| Brooks Laboratories Limited | 248.6 Million INR | -225353.437% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -48001.116% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | -583.095% |
| NATCO Pharma Limited | 10.53 Billion INR | -5221.682% |
| Suven Life Sciences Limited | 148.62 Million INR | -377019.99% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -18746.527% |
| Strides Pharma Science Limited | 37.68 Billion INR | -1387.453% |
| Indoco Remedies Limited | 10.34 Billion INR | -5319.293% |
| Alpa Laboratories Limited | 307.12 Million INR | -182394.09% |
| Lasa Supergenerics Limited | 541.92 Million INR | -103323.813% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -14297.48% |